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In this, O Nature, yield I pray to me.
I pace and pace, and think and think, and take
The fever’d hands, and note down all I see,
That some dim distant light may haply break.
The painful faces ask, can we not cure?
We answer, No, not yet; we seek the laws.
O God, reveal thro’ all this thing obscure
The unseen, small, but million-murdering cause.
(Sir Ronald Ross 1895)
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1 Zusammenfassung
Die vorliegende Studie wurde zwischen Juni und August 2010 in Mae Sot, einer Stadt
im Nordwesten von Thailand an der Grenze zu Myanmar durchgeführt. Dieses Gebiet
ist bekannt für seine multiresistenten P. falciparum Stämme. Das Ziel dieser in-vitro
Studie war die Aktivität, Sensibilität sowie die Interaktion von Artemisinin, E. longifolia
Extrakten und Kombinationen aus beiden gegen P. falciparum zu testen.
Für die Untersuchungen wurde der WHO Standard in-vitro Test Mark III zur Messung
der Schizontenreifungshemmung verwendet. Während der Studienzeit wurden 36 frische
Parasitenisolate positiv auf P. falciparum getestet. Von diesen konnten 29 Isolate in die
Studie aufgenommen werden.
Bei keiner der getesteten Substanzen konnte eine komplette Schizontenreifungshem-
mung festgestellt werden.
Die relative Schizontenreifungshemmung (SMI%) für Konzentrationen von 30 nmol/l
bis 3000 nmol/l war für Artemisinin zwischen 20,31% und 92,32%, for Eury-1 zwi-
schen 14,71% und 81,05%, für Eury-2 zwischen 14,47% und 82,02%, für Eury-3 zwi-
schen 12,38% und 85,31%, für Eury-1-Art zwischen 18,96% und 92,34%, für Eury-2-Art
zwischen 18,28% und 90,90% und für Eury-3-Art zwischen 18,69% und 93,03%.
Die durchschnittlichen EC50 Werte für Artemisinin, Eury-1, Eury-2, Eury-3, Eury-
1-Art, Eury-2-Art und Eury-3-Art waren 27,8586 nmol/l, 113,4614 nmol/l, 96,9067
nmol/l, 102,3605 nmol/l, 50,7239 nmol/l, 36,0345 nmol/l und 35,6274 nmol/l. Die durch-
schnittlichen EC90 Werte für die selben Substanzen in der gleichen Reihenfolge waren
1277,0471 nmol/l, 13874,2892 nmol/l, 7763,3631 nmol/l, 5323,0386 nmol/l, 2621,9225
nmol/l 1706,2443 nmol/l und 1415,4586 nmol/l. Die durchschnittlichen EC99 Werte für
die selben Substanzen in der gleichen Reihenfolge waren 28865,3737 nmol/l, 697799,1449
nmol/l, 276600,7487 nmol/l, 133347,3393 nmol/l, 65359,5184 nmol/l, 39,599,0921 nmol/l
und 28472,0333 nmol/l.
Sowohl der Vergleich der EC Werte mit den EC Werten aus 2009 als auch die Regres-
sionsparameter dieser zwei Jahre führte zu der Erkenntnis, dass die Wirksamkeit von
Artemisinin in diesem Gebiet nachgelassen hat.
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1 Zusammenfassung
In der Varianzanalyse zeigten die Substanzen Eury-1-Art und Eury-2-Art einen si-
gnifikanten Synergismus. Die Hemmung bei dem kombinierten Eury-3-Art Substrat war
höher als bei den einzelnen Komponenten Art mit Eury-3. Dieses Ergebnis könnte durch
die schwächere Wirkung von Artemisinin beeinflusst worden sein.
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2 Abstract
This study was carried out in Mae Sot, a town in north western Thailand on the border
to Myanmar between June and August 2010. This area is known for its multi-drug-
resistant strains of P.falciparum. The aim of this in vitro study was the assessment of
the activity and sensitivity of Artemisinin, E. longifolia analogs, combinations of both
and their interaction in P. falciparum.
The examinations were based on the WHO standard in vitro micro-test Mark III for
determining the inhibition of schizont maturation. Fresh blood isolates from 36 patients
were tested positive of P. falciparum. Out of them, 29 isolates could be included in the
study.
A complete cut-off concentration could not be calculated for any of the tested sub-
stances.
The observed inhibition of schizont maturation (SMI%) was for Artemisinin between
20,31% and 92,32%, for Eury-1 between 14,71% and 81,05%, for Eury-2 between 14,47%
and 82,02%, for Eury-3 between 12,38% and 85,31%, for Eury-1-Art between 18,96%
and 92,34%, for Eury-2-Art between 18,28% and 90,90% and for Eury-3-Art between
18,69% and 93,03% for concentration from 3 nmol/l up to 3000 nmol/l.
The mean EC50 values for Artemisinin, Eury-1, Eury-2, Eury-3, Eury-1-Art, Eury-2-
Art and Eury-3-Art were 27,8586 nmol/l, 113,4614 nmol/l, 96,9067 nmol/l, 102,3605
nmol/l, 50,7239 nmol/l, 36,0345 nmol/l and 35,6274 nmol/l. The mean EC90 val-
ues for the same substances in the same order were 1277,0471 nmol/l, 13874,2892
nmol/l, 7763,3631 nmol/l, 5323,0386 nmol/l, 2621,9225 nmol/l 1706,2443 nmol/l and
1415,4586 nmol/l. The mean EC99 values for the same substances in the same order
were 28865,3737 nmol/l, 697799,1449 nmol/l, 276600,7487 nmol/l, 133347,3393 nmol/l,
65359,5184 nmol/l, 39,599,0921 nmol/l and 28472,0333 nmol/l.
The comparison of the EC values with EC values from 2009 as well as the regres-
sion parameters of this two years lead to the assumption that there is a decrease in
effectiveness of Artemisinin in this area.
In the variance analysis the isolates showed in Eury-1-Art and Eury-2-Art a significant
13
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synergism. The inhibition under Eury-3-Art was higher than under separate compounds.
This might be influenced from the reduced activity of Artemisinin.
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3 Introduction
The human malaria parasites belong to the Domain: Eukaryota, Kingdom: Chroma-
lveolata, Superphylum: Alveolata, Phylum: Apicomplexa, Class: Aconoidasida, Or-
der: Haemosporida, Family: Plasmodiidae, Genus: Plasmodium (Wehner and Gehring,
2007).
The Genus Plasmodium (Marchiafava and Celli, 1885) can be further divided into two
subgenera: Plasmodium in the strict sense, where P. vivax (Grassi and Feletti, 1890),
P. ovale (Stephens, 1922) and P. malariae (Grassi and Feletti, 1890) belong to and
Laverania with P. falciparum (Welch, 1897) as the only agent. (Garnham, 1988)
3.1 History of malaria
Human being and the malaria parasites have a common evolutionary history. There
are different theories from where and how Plasmodium may have evolved. According
to Garnham (1966) the quartan malaria parasite appeared and evolved together with
the first prosimian in the Eocene, the tertian group in the Oligocene together with the
main simians. The subgenera Laverania at the time when higher apes and early man
separated. (Bruce-Chwatt, 1988)
With this theory it seams that host-parasite relation started in tropical Africa when
humans still lived as nomads. This way of life limited the malaria transmission. In the
Neolithic revolution with settlements, agriculture and migration along river valleys in
India, south China, Mesopotamia and the Nile valley the population began to grow.
Together with the warm climate and good breading conditions for mosquitoes due to
periodic inundations of the rivers the infection started to spread, so malaria endemicity
began. Along with human migration also malaria conquered other parts of continents.
Whereas the spread of malaria on the American continent is not fully clear, the rather
cold climate in Europe was limiting the malaria transmission to warm seasons. (Bruce-
Chwatt, 1988)
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Evidence of malaria parasites in humans can be found in ancient texts and human
findings. So seamed to exist malaria in Thailand 4000 years ago. This is based on ex-
amination of human bones, where severe anemia was observed, which could be a sign of
chronic malaria. In ancient texts from Egypt different types of fever sometimes accom-
panied with enlarged spleen were described, which lead to the assumption of malarial
origin. Enlarged spleens have also been found in Egyptian mummies about 3000 years
old. (Poser and Bruyn, 1999)
In China different types of fever with enlarged spleen were already mentioned in docu-
ments 2700 BC. For treatment, together with acupuncture, exorcisms and other plants,
they used Ch’ang shan (Dichroa febrifuga) which is known to have some antimalarial
effect. The first evidence for the use of Qinghaosu (Artemisia annua), which is now the
standard treatment of P. falciparum malaria, can be found in Chinese documents 340
AD. (Bruce-Chwatt, 1988)
The first clear description of the different fever attacks together with other symptoms
like splenomegaly, cachexia and bilious complexions is found in Hippocratic book of
endemics of the fourth century BC. But not only the clear description, also a coherence
between the fever, marshes and even division of low, moist and hot districts and the risk
involved is documented. Even though Hippocrates thought the disease was caused by
drinking the stagnant water. (Poser and Bruyn, 1999)
The Roman history is strongly associated with malaria, even if the first appearance
of the disease is not clear. But the intermittent fever related with swampy areas can
be found in many Latin documents starting in the first century BC. At the time the
malaria burden became so severe that they built a temple for the goddess Febris Magna
and might even play an important role at the fall of the Roman Empire. (Bruce-Chwatt,
1988)
In following centuries malaria stayed a great burden almost all over Europe without
treatment and caused many deaths. Before the discovery of the Cinchona bark, many
different, for present times scurrilous ways of treatment for the intermittent fever are
suggested in papers all over the world. There are also different stories from whom and
when and how the Cinchona bark was discovered and used first. The only thing which
seams to be clear, is the finding of it in the late sixteenth or early seventeenth century
somewhere in Peru. And that it was brought to Europe and promoted around 1730 by
Jesuits, thats why it was also called ’Cardinal’s Powder’ and ’Jesuits’ Bark’. The active
agent of the Cinchona bark is known today as Quinine. (Poser and Bruyn, 1999)
Despite this effective medicine of the Cinchona bark against malaria, the disease was
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3.1 History of malaria
still widely distributed all over the world in the nineteenth and beginning of the twentieth
century, even up to Canada and the Arctic Circle in Europe, pictured in Fig. 3.1.
Almost 90% of the world population was living in malaria endemic areas (Wernsdorfer
and Wernsdorfer, 2003; Poser and Bruyn, 1999).
Figure 3.1: Malaria distribution in the mid-19th century
Source: Wernsdorfer and Wernsdorfer, Malaria at the turn from the 2nd to the 3rd millennium
The term ’Malaria’ origins from Italian and means ’bad air’, was coined in the nine-
teenth century and referred to the fact that this periodic fever occurred in Europe mainly
in marshy areas and was caused by the ’bad air’ of these swamps (Poser and Bruyn,
1999).
In the nineteenth century the theory that malaria may be caused by a ’contagium
vivum’ a living microorganism and not by ’bad air’ was formulated. In 1880 Alphonse
Laveran, a French surgeon, discovered the actual parasite of malaria. But he falsely
thought that there was only one type of parasite causing malaria. Camillo Golgi pro-
claimed in 1885, that there are distinct species causing tertian and quartan malaria. Up
to that point the parasites could only be seen in fresh blood, the development of staining
by Metchnikoff in 1886 and further developed by Dimitri Romanowsky in 1891 helped
to differentiate the plasmodial species, the further differentiation of the parasite species,
the life-cycle and the transmission through anopheline mosquito bites was discovered in
1897 by the British military doctor Ronald Ross. This was the final breakthrough in
malaria research. (Poser and Bruyn, 1999; Bruce-Chwatt, 1988)
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In the twentieth century malaria could be eradicated in some parts like Canada and
Sweden by changing the land use. This did not happen in other parts of the world. At
the end of the second world war dichloro-diphenyl-trichloroethane (DDT) was discovered
as a cheap, safe and potent insecticide. Together with the synthesized chloroquine group
of drugs it seamed to be the breakthrough in eradicating malaria from the world. This
method was working in USA, Europe, Australia and parts of northern Asia and led to a
reduction of endemicity in north Africa, southern Asia, western Oceania and other parts
of America (Gramiccia and Beales, 1988). By 1975 around 50% of the world population
lived in malaria free areas (Wernsdorfer and Wernsdorfer, 2003).
Between 1975 and 2000 due to resistance to DDT and antimalarial drugs and also as
an effect of the reduction in research and control efforts, malaria started to increase again
(Gramiccia and Beales, 1988). Even though malaria was eliminated from large areas of
China and by 2000 about 60% of the world population lived in malaria free areas, in
many parts of the world, especially sub-saharan Africa and civil war aﬄicted regions, an
improvement of the malaria situation cannot be seen in the near future. (Wernsdorfer
and Wernsdorfer, 2003; Gramiccia and Beales, 1988)
3.2 Epidemiological facts
In low-income countries malaria is one of the main causes of morbidity and mortality
(WHO, 2011).
According to the world malaria report released by the WHO (World Health Orga-
nization) in 2010, in 106 countries and areas malaria is endemic. Fig. 3.2 shows the
geographical distribution of malaria in 2007. In these countries an estimated 225 mil-
lion cases of malaria occurred among 3,3 billion people at risk in 2009. Compared with
the figures of 2005 this is a drop of 19 million reported cases. This seamed to be due
to impact of malaria control (WHO, 2010d). But these estimations are only based on
numbers of national malaria control programs and probably far from complete. The
incidence may probably be much higher.
The main malaria case reduction of 86% can be found in the European Region followed
by American Regions with 42%. In Rwanda, Sao Tome and Principe and Zambia an
increase of cases was reported, the reason is not clear. “The vast majority of cases in
2009 (78%) were in the African Region, followed by the South-East Asia (15%) and
Eastern Mediterranean Regions (5%).” (WHO, 2010d, p. 60)
More than 90% of the clinically manifest malaria cases are caused by P. falciparum,
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3.2 Epidemiological facts
Figure 3.2: Malaria distribution 2007
Source: http://www.mosqguide.org.uk/images/Malaria.jpg
which can manifest in severe malaria with fatal outcome and therefore the reason of
nearly one million deaths worldwide (Wernsdorfer and Wernsdorfer, 2003). The world
malaria report estimated a decrease of 20% of malaria deaths between 2005 and 2009
with the largest reduction in the Region of America (WHO, 2010d). But again these
are only numbers of national malaria control programs.
“It is estimated that 91% of deaths in 2009 were in the African Region, followed by the
South-East Asia (6%) and Eastern Mediterranean Regions (2%). About 85% of deaths
globally were in children under 5 years of age.” (WHO, 2010d, p. 60)
The WHO and some partners started the roll back malaria program to reduce the
malaria burden in the world. The main goal of this program is to reduce the number of
malaria cases and deaths by 75% or more by 2015.
Strategies to attain this target are that: “countries must reach all persons at risk for
malaria with an insecticide-treated mosquito net (ITN) or indoor residual spraying (IRS)
and provide laboratory-based diagnosis for all suspected cases of malaria and effective
treatment of all confirmed cases.” (WHO, 2010d, p. xiii)
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3.3 The Parasite
The species Plasmodium with around 100 subspecies is part of the suborder Protozoa.
Out of these 100 only 6 are human pathogen, P. falciparum, P. vivax, P. ovale which
are obligate human pathogen, P. malariae in human and other primates, P.knowlesi
(Sinton and Mulligan, 1932) and P. cynomolgi (Mayer, 1907) usually in primates but
facultative also in humans. The rest is hosted in simians, birds and reptiles. (Wernsdorfer
and Wernsdorfer, 2010)
3.3.1 Plasmodium falciparum
Figure 3.3: Different stages of P. falciparum in erythrocytes
(Source: http://hermes.ffn.ub.es/oscar/Biologia/Malaria/Malariafalcip.gif)
P. falciparum is the pathogenic agent of malaria tropica and is responsible for almost
all severe cases and malarial deaths. If untreated usually 25% of P. falciparum infections
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have a lethal outcome in nonimmune persons. The specially unpleasant and dangerous
effect of P. falciparum malaria is its potential to invade all ages of Red Blood Cells
(RBC), hence the parasitaemia can be up to 50%, its incubation period of 8-11 days and
the occurrence of schizogony in deep capillaries. The infected RBC become physically
altered and tend to adhere to the internal lining of the capillaries. Together with changes
in the capillary walls themselves, this has the effect of producing microcirculatory arrest
in different organs like stomach, brain, kidney, liver, lungs and can also lead to ‘algid
malaria’. (Lucius and Loos-Frank, 2008; Garnham, 1988)
That a parasite is killing his host leads to the hypothesis that P. falciparum is, in
evolutionary terms, a relatively young parasite (about 10000 years old). Well adapted
parasites tend not to kill their host, because they need them to survive themselves.
(Lucius and Loos-Frank, 2008)
Compared to the other plasmodium species the incubation is relatively short, and one
erythrocyte can be invaded by more than one parasite or often shows double chromatin.
A mature schizont, which cannot be seen in the peripheral blood, contains 24-36 mero-
zoites, the duration of the erythrocytic schizogony is 48 hours and is not synchronized.
That is why the fever pattern is continuously with temperatures up to 40℃, but without
periodic intervals. The gametocytogenesis takes 12 days, the gametocytes are ovoid and
can appear in a blood film if the infection stays 8-10 days in the host. The different
stages of P. falciparum can be seen in Fig. 3.3. An untreated primary attack usually
lasts around 2-3 weeks. True relapses from the liver do not occur, and recurrences after
a year are rare. The maximum duration of P. falciparum in the host is about 4 years.
(Wernsdorfer and Wernsdorfer, 2010; Lucius and Loos-Frank, 2008)
The sporogony of P. falciparum in the mosquito needs a relative high temperature
>18℃, hence why the distribution of P. falciparum malaria occurs mainly in the tropes.
(Lucius and Loos-Frank, 2008; Garnham, 1988)
People living in a holoendemic area can acquire a partial immunity, which can be
passive or active. New born get the passive immunity from their immune mother through
transport through the placenta. This will last for the first months. Thereafter and till
the age of five, the highest mortality rates can be found. Children at the age of five to six
years develop an active immunity so the mortality rates decrease. Due to the acquired
immunity the parasitaemia is lower and the clinical symptoms are less severe. Without
repeated infections the immunity will disappear within a year. (Troye-Blomber et al.,
1999)
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3.3.2 Plasmodium vivax
Figure 3.4: Different stages of P. vivax in erythrocytes
(Source: http://upload.wikimedia.org/wikipedia/commons/6/60/Plasmodiumvivax.jpg)
P. vivax is the pathogenic agent, next to P. ovale of the malaria tertiana. The
distribution of P. vivax is worldwide due to relatively low average temperature of 16℃
needed for the sporogony in the mosquito. It is predominant in India, Central and South
America and eastern Asia, but it is absent in areas where people live with Duffy negative
antigens on erythrocytes, which occur mainly in West Africa. (Lucius and Loos-Frank,
2008; Garnham, 1988)
The incubation period of P. vivax is 8-17 days. The merozoits can only enter reticulo-
cytes, the young RBC. Therefore the parasitaemia is usually limited to 2%. The invaded
RBCs are enlarged and have tiny reddish granules, so called “Schüffner dots”. The ery-
throcytic schizogony takes 48 hours and is synchronized. Malaria tertiana has its name
because of this erythrocytic schizogony, with fever attacks every 48 hours, according to
the roman counting where day one is the day with the first fever attack. Mature sch-
izonts contain 16-24 merozoits. The duration of the gametocytogenesis is 48-96 hours
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and the gametocytes are round. Different development stages of the parasite can be
seen in Fig. 3.4. As a speciality P. vivax can form hypnozoits, which can survive in the
hepatocytes of the human liver and cause relapse after months to years. An untreated
primary attack usually lasts around 12-15 cycles till cure. But due to the hypnozoits,
relapse can appear up to 5 years, which is the maximum duration of the parasite in the
host. (Lucius and Loos-Frank, 2008; Markell et al., 1999)
Even though P. vivax malaria is regarded to be ‘benign’, the attacks have a serious
course, with fever up to 40,5℃, chills and rigor to last four to eight hours. Very sel-
dom are severe cases with splenic rupture, pulmonary injury and even cerebral malaria.
(Mendis et al., 2001)
3.3.3 Plasmodium ovale
Figure 3.5: Different stages of P. ovale in erythrocytes
(Source: http://static.periscopepost.com/wpcontent/uploads/2010/04/Povale.gif)
The appearance of P. ovale is generally rare and its distribution mainly in the tropical
Africa. Sometimes there are reported cases in South America and Asia. There are many
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similarities in morphology and symptoms to P. vivax, but the clinical picture is not as
severe. (Lucius and Loos-Frank, 2008; Markell et al., 1999)
Like P. vivax, the merozoits of P. ovale can only invade reticulocytes and also the in-
cubation period is almost the same. The invaded RBCs are enlarged and show Schüffner
dots as well, but have a typical ovoid form which gave the name to the parasite. The ery-
throcytic schizogony takes 48 hours and is synchronized, which again leads to a malaria
tertiana. But compared to P. vivax there are less merozoits (8-12) in a mature schizont.
With 48-96 hours the duration of the gametozytogenesis is the same as well. Different
stages of P. ovale in RBCs can be seen in Fig. 3.5. An untreated infection can last up
to 7 years in the host, the hypnozoits from the hepatocytes can cause relapses. (Markell
et al., 1999; Garnham, 1988)
3.3.4 Plasmodium malariae
Figure 3.6: Different stages of P. malariae in erythrocytes
(Source: http://www.bioon.com/Article/ UploadFiles/200406/20040603215831151.gif)
P. malariae is the pathogenic agent of malaria quartana. The distribution of P.
malariae malaria is mainly in western and eastern Africa and parts of India, but generally
very rare. (Lucius and Loos-Frank, 2008; Markell et al., 1999)
The incubation period is 18-40 days. Merozoits from P. malariae can only invade
old RBCs, therefore the parasitaemia is most of the time less than 1%. The RBCs
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are not enlarged and have no Schüffner dots. The name malaria quartana, is owed
to the fact that the fever attacks are every 72 hours, which is also the time for the
synchronized erythrocytic schizogony. Trophozoites tend to form the characteristic band
form. Shown, together with other stages in Fig. 3.6. A mature schizont contains 6-8
merozoits, which are typically arranged in a rosette, the so called ‘daisy head’. The
duration of the gametozytogenesis is 72-120 hours, but the round gametocytes usually
appear some weeks after the initial fever attack. An untreated primary attack usually
lasts for 3-24 weeks. The attacks are not as severe as P. vivax malaria, but last longer
and sometimes nephrotic syndromes can occur as complications. P. malariae does not
form hypnozoits, but it can still come to relapse even 50 years after primary infection.
(Lucius and Loos-Frank, 2008; Markell et al., 1999; Garnham, 1988)
Due to the fact that P. malariae malaria is the most benign of all plasmodial infections,
it seams that on a phylogenetic base it is the oldest and most adapted plasmodial species.
But there are already evidences against this theory. (Garnham, 1988)
3.4 The Life cycle
The life cycle of plasmodia, pictured in Fig. 3.7, is divided in an asexual cycle in the
human being and a sexual cycle in the female Anopheles (Meigen, 1818) mosquito (Nauck
et al., 1967).
3.4.1 Liver phase
The target of the sporozoites, which are imported through an infected mosquito bite,
are the liver cells. They reach the cells by circulating for a short time in the blood
stream. In the hepatic cells they develop into exoerythrocytic schizonts within 5-15
days, depending on the plasmodial species (Fujioka and Aikawa, 1999), 5,5 days in P.
falciparum, 8 days in P. vivax, 9 days in P. ovale, and 15 days in P. malariae (Aikawa,
1988). P. cynomolgi, P. vivax and P. ovale now also develop their dormant stage the
hypnozoites, which can turn into exoerythrocytic schizonts and appear as relapse even
after years (Fujioka and Aikawa, 1999). A mature exoerythrocytic schizont contains
2000-40000 merozoits depending on the plasmodial species (P. malariae ∼ 2000, P.
ovale ∼ 15000, P. vivax ∼ 10000 and P. falciparum 20000-40000) (Wernsdorfer and
Wernsdorfer, 2010). The hepatocytes rupture and merozoits are released to the blood
stream and invade RBCs within 30 seconds. Now the erythrocytic cycle begins. (Fujioka
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Figure 3.7: Life Cycle of Plasmodia
(Source: http://www.jci.org/articles/view/33996/files/JCI0833996.f1/medium)
and Aikawa, 1999)
3.4.2 Blood phase
The development in the RBCs from merozoits through ring, trophozoites and schizonts is
called the erythrocytic schizogony (Fujioka and Aikawa, 1999). In most species the mero-
zoits in the RBCs have only one nucleolus and cytoplasm. By digesting the haemoglobin
and developing a vacuole they grow to trophozoits. Further on the nucleolus begins to
divide and becomes a schizont (Aikawa, 1988). After maturation of the schizont with
the species specific amount of merozoits, (mentioned in 3.3.1, 3.3.2, 3.3.3, 3.3.4) the
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RBCs bust and the released merozoits invade again new RBCs. After several of these
erythrocytic cyles, some of the merozoits turn into sexual forms, the female macroga-
metocytes and the male microgametocytes. This is called the gametocytogony. (Fujioka
and Aikawa, 1999)
3.4.3 Mosquito phase
After intake of this sexual form via a blood meal in the mosquito midgut, the macrogame-
tocytes leave the erythrocytes and form macrogametes. The microgametocytes exflagel-
late and form eight microgametes. After fertilization of a macrogamete with a microga-
mete a zygote is formed, which develops within 18-24 hours to an ookinet. The ookinet
moves through the peritrophic membran and the epithelial cells. Beneath the basement
membrane of the midgut epithelium they turn into an oocyst. An oocyst releases up to
10000 sporozoits, which move to the salivery glands and accumulate there. In case this
infected mosquito takes another blood meal from a human being, the life cycle starts
again. (Fujioka and Aikawa, 1999)
3.5 The Vector
Figure 3.8: Anopheles gambiae
(Source:
http://www.raywilsonbirdphotography.co.uk
/Anophelesgambiae.jpg)
The obligate vector for all human pathogen plasmod-
ium are the female anopheline mosquitoes. An ex-
ample pictured in Fig. 3.8 with A. gambiae. Out of
the currently known 420 different anopheline species,
around 67 merit consideration as malaria vectors, but
roughly half of them are responsible for the most
transmissions. (Wernsdorfer and Wernsdorfer, 2010)
The distribution of the anopheline mosquitoes is
not restricted to the tropics and subtropics, they are
found worldwide, even in the arctic territories. But if
a mosquito is able to transmit malaria, many factors
have to accord. Some of these differences in malaria
infection and transmission may be due to differences in preference for human blood
(anthropophilism) or for animal blood (zoophilism). Another factor is the temperature,
the sporogony in the mosquito can only take place at a temperature between 16℃
and 33℃. Therefore a temperature range between 20℃ and 30℃ and humidity form
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the optimum conditions. Partially this is also depending on the different plasmodial
species, e.g. P. vivax can stand lower temperatures whereas P. falciparum needs higher
temperatures. Some other important conditions are the lifespan of the mosquito, the
duration of blood meals (at least two are needed for transmission), the breeding and
living preferences and the frequency of occurrence of female mosquitoes. (Wernsdorfer
and Wernsdorfer, 2010; Lucius and Loos-Frank, 2008; Weyer, 1939)
3.6 Clinical symptoms of P. falciparum
P. falciparum malaria or malaria tropica can roughly be divided into uncomplicated and
severe malaria (Harinasuta and Bunnag, 1988).
3.6.1 Uncomplicated malaria
The first symptoms appear 8-12 days after the bite of an infected mosquito and are
not specific. With headaches, fatigue, muscle and joint pain, nausea, diarrhea followed
by chills, fever and vomiting, it is difficult to distinguish from influenza or other viral
infections. In the early stage of the infection the fever pattern is continuous remittent but
without periodicity. Mild anemia and enlarged spleen might also be found, especially in
patients with constant re-infections. With proper treatment in this stage, the infections
can be fully cured. Without treatment the primary attack can lead to severe malaria
and can be fatal to non immune people. (WHO, 2010b; Harinasuta and Bunnag, 1988)
3.6.2 Severe malaria
Although about one percent of all malaria cases turn into severe malaria, it is still
responsible for around one million deaths each year in sub-Saharan Africa (Mackintosh
et al., 2004).
The reason for the manifestation of severe malaria is the fact that infected RBCs tend
to adhere in the small blood vessels and block the blood supply to organs. This can
appear suddenly and at any stage of the infection. (Harinasuta and Bunnag, 1988)
Definition of severe P. falciparum malaria according to WHO
“In a patient with P. falciparum asexual parasitaemia and no other obvious cause of
symptoms, the presence of one or more of the following clinical or laboratory features
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classifies the patient as suffering from severe malaria:
Clinical features:
• impaired consciousness or unrousable coma
• prostration, i.e. generalized weakness so that the patient is unable walk or sit up
without assistance
• failure to feed
• multiple convulsions - more than two episodes in 24 h
• deep breathing, respiratory distress (acidotic breathing)
• circulatory collapse or shock, systolic blood pressure <70 mm Hg in adults and
<50 mm Hg in children
• clinical jaundice plus evidence of other vital organ dysfunction
• haemoglobinuria
• abnormal spontaneous bleeding
• pulmonary oedema (radiological)
Laboratory findings:
• hypoglycaemia (blood glucose <2.2 mmol/l or <40 mg/dl)
• metabolic acidosis (plasma bicarbonate <15 mmol/l)
• severe normocytic anaemia (Hb <5 g/dl, packed cell volume <15%)
• haemoglobinuria
• hyperparasitaemia (>2% /100000/µl in low intensity transmission areas or >5%
or 250000/µl in areas of high stable malaria transmission intensity)
• hyperlactataemia (lactate >5 mmol/l)
• renal impairment (serum creatinine >265 µmol/l).”
(WHO, 2010b, p. 35)
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3.7 Diagnosis of malaria
3.7.1 Symptom-based diagnosis
As mentioned in 3.6 the clinical symptoms of malaria, e.g. headache, fever, chills and
fatigue, are very general. Therefore they fit to quite a number of other diseases and
also vary in different areas. A diagnosis of malaria based only on symptoms is low in
sensitivity and specificity. Even if a detailed weighting and scoring system can improve
this, it is still not accurate enough and might be too difficult to implement and supervise.
On the one hand a symptom-based diagnosis of malaria may lead to an over diagnosis.
On the other hand also to under diagnosis. Nevertheless to know the symptoms is
important for the initial thought to get to the right diagnose (WHO, 2010b; Gilles,
1988).
3.7.2 Rapid diagnostic tests
According to the WHO “Rapid diagnostic tests (RDT) are immunochromatographic tests
that detect parasite-specific antigens” (WHO, 2010b, p. 118). RDTs can be divided
into four groups of antigen targets: histidin-rich protein 2 (HRP2), parasite lactone
dehydrogenase (pLDH), Plasmodium aldolase and the fourth not further identified is
specific to P. vivax (Murray et al., 2003). Many different tests from various producers
are available to detect P. falciparum, most of them use HRP2 or pLDH or both (WHO,
2008).
Compared to microscopy, the advantage of RDTs is the simplicity in performance,
interpretation and rapid results. To perform the test, there is no laboratory required,
not even electricity and the health workers need to be trained but less skilled (WHO,
2010b).
But there are also limitations of this test method, for example the sensitivity. Most
tests have limitations to detect low parasite density (200 parasite/µl), but good detection
at 2000-5000 parasites/µl (WHO, 2008). Another limitation is the specificity, many
of these test only differentiate P. falciparum and non-P. falciparum, but the non-P.
falciparum are not clearer defined (Murray et al., 2003). In P. falciparum there are
also difficulties to differ new infections from effectively treated infections in the last
three weeks, due to the persistence of HRP2 in the blood after treatment (WHO, 2010b;
Murray et al., 2003). There can also be false-positive results from patients with acquired
immunity or rheumatoid factors (WHO, 2008; Murray et al., 2003)
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However RDTs can be a good alternative to reduce anti-malarial overuse in areas with
low transmission and poor settings. But it is important to ensure the good quality and
storage of the tests and well trained health workers (WHO, 2010b; Murray et al., 2003).
3.7.3 Microscopic diagnosis
The light microscopy should be the ‘field standard’ in malaria diagnosis (WHO, 2010b).
There are two ways of examination, a ‘thick film’ and a ‘thin film’. In the thick film
many layers of red and white blood cells upon each other, so the parasites are more
concentrated and therefore easy to find and identify. This method is used to search for
parasites. A thin film, if properly made, consists only of one layer of blood cells. This
method is used to confirm the plasmodial species and only in exceptions for parasitic
search (WHO, 1991).
Preparation of a thick film
Before starting, the patients data need to be recorded and the slide appropriately labeled.
After disinfection and drying, the finger tip is pricked with a sterile lancet. Two or three
large drops of blood are placed close together in the middle of the slide. To make an
even thick film with a diameter of about one centimeter, the drops are joined with some
strokes using the corner of another slide. Before staining, the slide needs to fully dry.
(WHO, 1991)
Giemsa stain
Giemsa is the most commonly used stain for the diagnosis of malaria on blood smears
(Shute, 1988).
“Giemsa stain is an alcohol-based Romanowsky stain. Giemsa stain is a mixture
of eosin, which stains parasite chromatin and stippling shades of red or pink, and
methylene blue, which stains parasite cytoplasm blue. White-cell nuclei stain blue to
almost black, depending on the type of white cell. During staining, the hemoglobin
in the red cells dissolves (dehaemoglobinization)” (WHO, 1991, p. 32).
For the rapid staining a 10% solution of Giemsa in a buffered water (pH 7,2) is used,
about 3-5 ml for each slide. Staining time is eight to ten minutes. After that the slides
need to be washed gently with plain water and dried properly in a drying rack. (WHO,
1991; Shute, 1988)
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Examination blood films for malaria parasites
The examination of blood films for malaria parasites is done by light optical microscope
using a x10 paired oculars and x100 oil immersion objective (WHO, 1991).
“Using the fine adjustment, focus on the cell elements and confirm that the portion of
the film is acceptable for routine examination: 15-20 white blood cells per thick film
field will give a satisfactory film thickness. Films with fewer white blood cells per
field will require more extensive examination. Routine examination of a thick film
is based on examination of 100 good fields; i.e. a slide can be pronounced negative
only when a minimum of 100 fields have been carefully examined for the presence of
parasites.” (WHO, 1991, p. 72).
In a positive slide the parasite species needs to be identified and the density to be
counted against white blood cells (WHO, 1991).
For microscopical diagnosis of malaria high costs in setting up, training and supervi-
sion are involved and the maintainability might be difficult. But if this is done, it is the
method with the highest sensitivity and specificity. (WHO, 2010b)
3.8 Antimalarial drugs
Since malaria is a serious disease, a proper treatment is important (WHO, 2010b).
3.8.1 Classification of antimalarial drugs
Anti-malarial drugs can be roughly classified according to their biological activity in
tissue schizontocides and blood schizontocides (Desjardins et al., 1988). This is listed in
Table 3.1.
Blood schizontocide (erythrocytic schizontocide): “refers to a drug which destroys
asexual parasites in the blood” (Desjardins et al., 1988, p. 828). Blood schizontocides
are used as treatment as well as prophylaxis, but do not work against intrahepatic forms.
Agents are: 4-Aminoquinolines, Arylaminoalcoholes and Artemisinin and its derivatives
(Stuart et al., 2008).
Tissue schizontocide (exoerythrocytic schizontocide): “refers to a drug which de-
stroys asexual parasites in the tissues” (Desjardins et al., 1988, p. 828), by inhibiting
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Table 3.1: Summary and biological activities of anti-malarial drugs
(0= no effect, + =effect, VMO=effective against P. vivax, P. malariae, P. ovale,
F=against P. falciarum)
Class Drug
Blood
schizon-
tocide
Tissue
schizon-
tocide
Mature
gameto-
cytes
4-Aminoquinolines Chloroquine ++ 0 VMO
Arylaminoalcohols Quinine ++ 0 VMO
Quinidine ++ 0 VMO
Mefloquine ++ 0 VMO
Phenoenthrene methanol Halofantrine ++ 0 0
Artemisinin and
derivatives
Artemisinin ++ 0 +
Artemether ++ 0 +
Artesunate ++ 0 +
Antimetabolites Proguanil + + 0
Pyrimethamine + 0 0
Sulfadoxine + 0 0
Antibiotics Tetracycline + F 0
Doxycycline + + 0
Clindamycin + + 0
8-Aminoquinoline Primaquine 0 + 0
(Stuart et al., 2008; Ridley, 2002; Desjardins et al., 1988)
early stages or destroying hynozoites. Agents are: 8-Aminoquinoline, Proguanil and
probable Pyrimethamine (Desjardins et al., 1988).
Gametocytocide: “refers to a drug which destroys the sexual forms of the parasite
in the blood” (Desjardins et al., 1988, p. 828).
3.8.2 Treatment of malaria
Since malaria is a complex disease with different activators, the following aspects have
to be considered before treatment is given:
• “The identity (species) of the Plasmodium with which the individual is infected or
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to which exposure is anticipated
• The severity of an existing infection including level of parasitemia and presence of
complications
• The anticipated level of immunity based on prior infection of exposure
• The likelihood of drug resistance based on geographical considerations
• The presence of special risk factors such as age, pregnancy and intercurrent illness
• The tolerability of specific drugs” (Desjardins et al., 1988, p. 828)
Treatment of uncomplicated P. falciparum malaria
For many years the standard therapy for uncomplicated P. falciparum malaria was
Chloroquine. But now there is a resistance to Chloroquine in almost all parts of the
world as well as to sulphadoxine/pyrimethamine. (Ridley, 2002)
The standard therapy recommended from the WHO is now a combination of two blood
schizontocides with different way of action, to reduce the risk of resistance. One of this
medications should be an artemisinin derivative (Stuart et al., 2008). This treatment
regime is called Artemisinin-based combination therapy (ACT).
There are four oral ACTs recommended at this time:
• artesunate plus mefloquine (AS+MQ) in Asia
• artemether plus lumefantrine (AL) worldwide
• artesunate plus amodiaquine (AS+AQ) worldwide
• artesunate plus sulfadoxine-pyrimethamine (AS+SP)
(WHO, 2010b)
Artemisinin is contraindicated during the first trimester of pregnancy. In this period
Quinine as a monotherapy or in combination with clindamycin should be given. (Stuart
et al., 2008)
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Treatment of severe P. falciparum malaria
Severe P. falciparum malaria is an emergency with a high mortality rate and needs to
be treated in a hospital with prompt parenteral antimalarials and good medical care
(WHO, 2010b).
There are two treatment regimes recommended from theWHO, intravenous Artemether
or Artesunate or Quinine. Artesunate should be given in non-endemic areas with low
to moderate transmission. In areas with high transmission the treatment of choice is
intravenous Artemether or Quinine. (WHO, 2010b; Stuart et al., 2008)
Since Quinine causes a range of side effects it should only be given if other recom-
mended parenteral antimalarials are not present (WHO, 2010b).
When the patients get better after the initial parenteral treatment and can tolerate
oral medications, a full course of oral ACT should be given (WHO, 2010b).
Treatment of P.vivax, P. ovale, P. malariae malaria
The current WHO recommendation to treat the so called benign malarias is still Chloro-
quine. In areas with Chloroquine resistance, Amodiaquine or an Artemisinin derivative
or Mefloquine should be given. The hypnozoites from P. vivax and P. ovale must be
treated with Primaquine for radical cure. (Stuart et al., 2008)
“In pregnant patients with P. vivax or P. ovale infections, radical cure with Pri-
maquine should be postponed until after delivery; Chloroquine at a dose of 600 mg
weekly can be given until then.” (Stuart et al., 2008, p. 189)
3.9 Antimalarial drug resistance
Resistance to antimalarial drugs has been defined by the WHO in 1965 as the “ability of
a parasite strain to survive and/or multiply despite the administration and absorption
of a drug given in doses equal to or higher than those usually recommended but within
tolerance of the subject”. And was modified by Bruce-Chwatt L.J. 1981 that the drug
must “gain access to the parasite or the infected red blood cell for the duration of the
time necessary for its normal action” (Bloland, 2001, p. 12).
Malaria with its estimated one million deaths each year is one of the greatest disease
burdens in the world, even more with antimalarial drug resistance (Wongsrichanalai
et al., 2002). The distribution of resistance can be seen in Fig. 3.9.
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Out of the four human pathogen plasmodial species, P. falciparum is the one with a
comprehensive resistance to quite some drugs. A resistance to chloroquine in P. vivax
can be found in some parts of the world. In P. ovale and P. malariae resistance is not
documented yet. (Wongsrichanalai et al., 2002; Bloland, 2001)
Chloroquine resistant P. falciparum strains are documented, except of Central Amer-
ica and the Caribbean, in all areas where P. falciparum is endemic. In the late 1950s
the first Chloroquine resistance to P. falciparum was reported at the Thai-Cambodian
border and in Colombia, followed by Africa in 1978 in the east and covered this conti-
nent by 1983 and South America in the 1980s. By 1989 (with Asia and Oceania) the
resistance was worldwide. (Wongsrichanalai et al., 2002)
P. falciparum resistance to sulfadoxine-pyrimethamine (SP) started again on the Thai-
Cambodian border and is constantly increasing in Africa where it is used as a substitution
for chloroquine (Wongsrichanalai et al., 2002; Bloland, 2001).
Up to now resistance from P. falciparum to mefloquine as well as artemisinin and
derivatives occur only in some parts of south-east Asia and Africa (Wongsrichanalai
et al., 2002; Bloland, 2001).
If a parasite is resistant and not only to the first two antimalarial drug classes (4-
aminoquinolines e.g. chloroquine and antifolates e.g. SP) but also to a third class, it is
called a Multi-drug-resistance (MDR) (Wongsrichanalai et al., 2002).
Figure 3.9: Antimalarial drug resistance to P. falciparum according to WHO
Source: Wongsrichanalai et al. (2002)
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3.9.1 Mechanism of antimalarial resistance
There are different ways of how a parasite can acquire a resistance to drugs:
A resistance can occur through a spontaneous mutation, which makes the parasite less
sensitive to a drug or drug class. Sometimes a single mutation is enough to make a
parasite resist against a drug, for some drugs multiple mutations are needed. It does not
necessarily mean that all parasites of a population have the same range of resistance,
this can vary from completely sensitive to highly resistant. (Bloland, 2001)
Another way for example (chloroquine), that the parasite can increase his capacity to
excrete the drug through his food vacuole, so that the drug does not reach the necessary
level to inhibit the haem polymerization. If resistance to other quinolines develop with
the same mechanism is not yet proved. (Bloland, 2001)
Also the half-life of a drug can influence resistance. Drugs with a long half-life (SP,
MQ) decrease the duration of treatment and thus encourage the compliance, but also
increase the possibility of the parasite to develop resistance. This can happen especially
in areas with high transmission when the drug level drops below the level of full parasite
growth inhibition but stays above 5% inhibition. There is still selective pressure but not
enough to kill recrudescent parasites or from new infections. Due to this sub-therapeutic
drug level parasites can build up resistance. The same can happen, if medication is under
dosed either due to incorrect prescription or low patient compliance of dose or duration.
(Bloland, 2001)
In vivo, in vitro, animal model studies, and molecular characterization are the four
different ways how antimalarial resistance can be tested (Bloland, 2001).
3.9.2 Treatment failure
According to WHO “Treatment failure is defined as an inability to clear malarial para-
sitaemia or resolve clinical symptom despite administration of an antimalarial medicine.”
(WHO, 2010a, p. 9)
Not every treatment failure occurs due to drug resistance. There are many other
reasons, like incorrect dosage of drugs, non compliance of patients in duration or dosing
of drugs, poor absorption or fast elimination of drugs in very sick patients, poor quality
or expired drugs or drug interaction. (WHO, 2010a; Bloland, 2001)
Treatment failures are classified by the WHO in 2009 as follows:
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“Early treatment failure (ETF)
• danger signs or severe malaria on day 1, 2 or 3 in the presence of parasitaemia;
• parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature;
• parasitaemia on day 3 with axillary temperature is 37.5℃; or
• parasitaemia on day 3 is 25% of count on day 0
Late clinical failure (LCF)
• danger signs or severe malaria in the presence of parasitaemia on any day between
day 4 and day 28 (day 42) in patients who did not previously meet any of the
criteria for early treatment failure; or
• presence of parasitaemia on any day between day 4 and day 28 (day 42) with
axillary temperature >37.5℃ in patients who did not previously meet any of the
criteria for early treatment failure
Late parasitological failure (LPF)
• presence of parasitaemia on any day between day 7 and day 28 (day 42) with
axillary temperature <37.5℃ in patients who did not previously meet any of the
criteria for early treatment failure or late clinical failure
Adequate clinical and parasitological response (ACPR)
• absence of parasitaemia on day 28 (day 42), irrespective of axillary temperature,
in patients who did not previously meet any of the criteria for early treatment
failure, late clinical failure or late parasitological failure” (WHO, 2010a, p. 90)
From a contemporary perspective, malaria is not going to be eradicated in the close
future, consequently effective antimalarials are going to be needed. As long as drugs
are in use, there is always a risk that parasites develop resistance. To minimize the risk
of resistance drugs pressure needs to be reduced by correct diagnosis and prescription,
good patients compliance and the use of drug combinations. (Bloland, 2001)
38
4 Methods and Material
4.1 Study area
Figure 4.1: Map of Thailand
(Source:http://www.beepworld.de)
The study was carried out in the Malaria Clinic
in Mae Sot, Thailand. Mae Sot is a town in the
Tak province, about 550km northwest of Bangkok
on the border to Myanmar, shown in Fig. 4.1. The
Moei River is the natural border between these two
countries and the surroundings are forest hills where
malaria transmission is high. (Knauer et al., 2003)
Tak province is one of the regions in Thailand
which suffers most of malaria. One of the reasons
for this situation is the heavy border traffic be-
tween Myanmar and Thailand due to labor migra-
tion. Most of the population is located in remote
and rural areas surrounded by rice and cotton pad-
dies and mountains with little access to health care.
(WHO, 2007)
The main malaria vectors in this region and typical
for forest areas are Anopheles dirus and Anopheles
minimus. The malaria transmission period shows two peaks, one during rainy season
between May and September and the second in November and December, but can gen-
erally occur at any time of the year. (Knauer et al., 2003) Malaria is endemic in this
region, with P. vivax as the leading species (approximately 60%), followed by P. falci-
parum (approximately 40%). Mixed infections and other species such as P. malariae
are rarely seen. (WHO, 2010c)
The standard treatment of uncomplicated P. falciparum malaria is an oral combina-
tion therapy of Mefloquine and Artesunate. Irrespective of their nationality, the treat-
ment for all patients with malaria in Thailand is free of charge. This governmental
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program aims at preventing the increase of drug resistance due to self treatment with
incorrect use of drugs and low compliance. (WHO, 2010c)
The samples were taken between end of June 2010 and beginning of August 2010.
The cases were diagnosed from the medical assistants of the local malaria clinic with
Giemsa-stained thick blood film and microscope.
4.2 Patients
4.2.1 Including criteria
All patients came for treatment to the malaria clinic of Mae Sot. For inclusion in our
study they had to be above 9 years old (excluding pregnant women) and suffering from
P. falciparum mono infections with a parasitaemia between 1000 and 100000 asexual
parasites/micro liter blood.
Exclusive criteria, apart from childhood and pregnancy, were severe and complicated
malaria and a recent treatment with Mefloquin within the last 63 days all other anti-
malarial drugs and antibiotics within the last 14 days.
All P. falciparum malaria patients were treated with Artesunate and Mefloquine, the
standard therapy in Thailand, after confirmation of the diagnosis and blood sampling
for the in-vitro test.
Before a blood sample was taken, an oral informed consent was required from the
patients, including epidemiological data such as sex, age, nationality, occupation, place
of residence, origin of infection and the registration number of the Mae Sot Malaria
Clinic.
4.2.2 Epidemiology
During the period of the study in Mae Sot 36 patients were tested positive with P.
falciparum malaria. Out of this group 29 patients could be included in the study. Out
of this 29, 9 where female with an average age of 29,68 years. The remaining 20 male
patients had an average age of 30,74 years.
18 out of the 29 patients in the study had their residence in Thailand (3 female and
15 male), the other 11 (6 female and 5 male) lived in Myanmar.
Out of the 29 patients from the study, only 13 got their infection in Thailand, while
40
4.2 Patients
the remaining 16 got infected in Myanmar. This might be due to the poor health system
in Myanmar.
The most common occupation of the patients with P. falciparum malaria was farmer
with 15 individuals, followed by 5 labourers (mainly woodcutters) and 5 workers. These
findings are not uncommon since people with outdoor activities are more exposed to
mosquitoes.
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4.3 Substances tested
In the study Artemisinin (explained in 4.3.1) and extracts from E. longifolia (explained
in 4.3.2) were tested. Also combinations of Artemisinin and extracts from E. longifolia
were tested to prove an interaction.
4.3.1 Artemisinin
Figure 4.2: Artemisinin
( Source: http://www.york.ac.uk/org/cnap/
artemisiaproject/images/artemsinin.gif)
Artemisinin, (structure shown in Fig. 4.2), was iso-
lated from Chinese scientists in 1971 from the leaves of
Artemisia annua. The indigenous plant, which grows
throughout China, is locally called Qinghao and is in use
as herbal medicine since more than 2000 years. (Werns-
dorfer and Trigg, 1988)
Artemisinin is a very stable sespquiterpene lactone
and almost insoluble in water, only sparingly soluble in
oils, but dissolve in ethyl alcohol and dimethyl sulfoxide
(DMSO). Because of the poor solubility of the parent com-
pound, Artemisinin, some halve synthetic derivatives like artemether, artesunate, ar-
teether, dihydroartemisinin and artelinic acid were metabolized. All of them are very
potent and rapid acting blood schizontocides and can be administrated in many differ-
ent ways, i.e. oral, intramuscular, intravenous and even rectal. (Krishna et al., 2004;
Meshnick et al., 1996)
There is no difference of bioactivity between Artemisinin and its derivatives, because
all are rapidly metabolized to di-hydroartemisinin (DHA) with a short half-live (Werns-
dorfer and Wernsdorfer, 1991).
In P. falciparum Artemisinin and its derivatives are active against the broadest age
range of the parasites, from tiny rings that have just invaded erythrocytes, up to mature
trophozoites and even schizonts. Which also impacts the mosquito transmission. But
they do not work against hepatic stages, therefore no prophylactic potential. Apart
from P. falciparum they are killing all human pathogen Plasmodium species. (Woodrow
et al., 2005)
The Artemisinins act faster than all other types of antimalarial, thus it is recommended
by the World Health Organization (WHO) in oral Artemisinin combination therapy
(ACT) as first line treatment for uncomplicated P. falciparum malaria. The combination
is necessary because Artemisinin and its derivatives have a very short half-life, so a
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treatment for seven days would be required. In combination with a slow elimination
antimalarial the treatment can be shortened to three days. A benefit from the ACT is,
that the partner compounds protect from resistance. (WHO, 2010b)
4.3.2 Extracts from Eurycoma longifolia
Figure 4.3: E. longi-
folia
( Source:
http://www.corenberg.com)
Eurycoma longifolia Jack is a plant in the family Simaroubaceae.
It is an evergreen flowering tree, shown in Fig. 4.3 on the left
side, indigenous to the jungles of Malaysia and Indonesia. In
the local traditional medicine several products, especially from
the roots pictured in Fig. 4.3 on the right side, locally known as
Tongkat Ali or Pasak Bumi, are used as antipyretic, antimalarial
and anabolic properties. (Wernsdorfer et al., 2009; Chan et al.,
2004)
In the late 20th century many substances from E. longifo-
lia Jack have been tested in different areas, for example their
anabolic properties (Muhamad et al., 2010) or their cytotoxic
activity against tumor cells (Zakaria et al., 2009; Tee and Azimahtol, 2005).
Figure 4.4: Structure of quassinoids from E. longifolia (1 = eurycomanone; 2 = 13,21-
dihydroeurycomanone; 3 = 13α (21)-epoxyeurycomanone)
Source: Wernsdorfer et al. (2009)
In previous studies (Chan et al., 2004; Jiwajinda et al., 2002; O’Neill et al., 1986) sev-
eral quassinoids from the roots of E. longifolia were tested for their antiplasmodial activ-
ity. Out of these, three standardized quassinoids, eurycomanone, 13,21- dihydroeuryco-
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manone and 12α(21)-epoxyeurycomanone (structure shown in Fig. 4.4) were isolated at
the University Sains Malaysia by Professor Kit Lam Chan and provided for our study.
The E. longifolia extracts where tested as followed:
1. Eury 1: eurycomanon (80%)
2. Eury 2: eurycomanon (80%) + 13,21- dihydroeurycomanone (4,9%)
3. Eury 3: eurycomanon (76%) + 13,21-dihydroeurycomanone (4,3%) + 12α (21)-
epoxyeurycomanone (2,3%)
4.4 In vitro test system
The examinations are based on the WHO standard in vitro micro-test Mark III for the
determination of drug sensitivity in P. falciparum . This test provides information about
sensitivity and drug response by measuring the inhibition of schizont maturation in fresh
blood isolates of P. falciparum . (WHO, 2001)
The pre-dosed test plates were prepared at the Institute of Specific Prophylaxis and
Tropical Medicine, Medical University of Vienna.
For the test, the RPMI 1640 LPLF-Medium is prepared with sodium bicarbonate
and Gentamycine, distributed in sterile plastic tubes à 900µl and stored at 4℃. After
disinfecting the puncture site (finger tip or earlobe) with an alcohol swap and drying
up, 100µl blood are taken in a sterile heparinized capillary tube, diluted into the serial
number labeled plastic tube with the medium and gently agitated (n.b. this amount
(1 ml) of blood-medium-mixture (BMM) is sufficient for two test columns). The BMM
can be kept up to 4 hours in the incubator at nearly 37℃. For longer storage the BMM
needs to be cooled down at 4℃, either in the refrigerator or on wet ice, without direct
contact to the tube. (WHO, 2001)
At the same time a thick blood film is prepared to determine the initial parasitaemia
of the patient to control the including criteria. This pre-incubation slides are read for
the number of asexual parasites per at least 200 leukocytes and calculated with the
following formula:
Parasites/µl = Number of parasites counted x 8000
number of leukozytes counted
(WHO, 1991)
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Table 4.1: Micro titre plate and concentrations of the substances used in the study
A B C D E F G H
Eury 1 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
Eury 2 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
Eury 3 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
Art 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
Art+Eury1 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
Art+Eury2 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
Art+Eury3 0 3 nM 10 nM 30 nM 100 nM 300 nM 1000 nM 3000 nM
For the test the appropriate drugs are dosed on sterile micro titre plates with 12
columns of 8 wells each, sealed with a transparent sheet and labeled with the containing
drug. The wells B to H are filled with increasing concentrations of the substances to be
tested, well A is as a control free of drugs. An illustration of a micro titre plate is shown
in table 4.1.
50µl aliquots of the BMM are added to well A-H of the scheduled test plates, beginning
by well A to prevent contamination. The dosed plates are closed with a sterile lid and
gently agitated in order to dissolve the drugs. The patients number, date and time of
inoculation are inscribed on the lid. After that, the plates are placed in a candle jar
(desiccator), containing a small container of water. The candle jar is sealed airtight,
after the candle exhaust it is put in the incubator at 37,5℃ for 24 to 26 hours. (WHO,
2001; Wernsdorfer and Wernsdorfer, 1995)
After incubation the test plates are removed from the candle jar and ‘harvested’ by
discharging the medium supernatant and preparing thick films from the sediments on
microscopy slides. Each test column is placed in a set order of eight thick films on one
slide, starting from well H up to well A. Each slide is labeled with patient number,
substance and date of test. (WHO, 2001)
The slides are then dried at least 24 hours. After drying they are stained with Giemsa
solution at pH 6,8 for 90 minutes. (Wernsdorfer and Wernsdorfer, 1995)
45
4 Methods and Material
4.5 Evaluation and statistical analysis
The reading of the thick blood films is done by a light optical microscope with x10 paired
oculars and x100 oil immersion objective (WHO, 1991).
In the evaluation, beginning with well A (control), the number of schizonts (≥ 3
chromatin dots) are counted against other asexual forms to a total of 200 parasites.
The slide is classified as valid, if the control shows either ≥ 20 schizonts in total or
≥ 10% schizonts of all asexual parasites in the count. Are these criteria fulfilled, the
reading can proceed with well B to H. Usually the number of schizonts decreases with
the increase of substanceconcentration, up to the point of total inhibition. The so-called
cut-off point or cut-off concentration gives a rough indication of the parasite sensitivity
to the testsubstance. (Wernsdorfer and Wernsdorfer, 1995)
The statistical evaluation is done by the classic method of Litchfield and Wilcoxon
(1949), based on the assumption of a log-normal distribution of drug resistance in all
parasite populations with no recent drug contact. The drug concentrations are trans-
formed into logarithms and the inhibition in % in probits. For the calculation of the
individual effective drug concentration (EC50, 90, 99), the % inhibition of schizont mat-
uration at given drug concentration (SMI%) and regression parameters, a computer
model of Wernsdorfer and Wernsdorfer (1995) is used. With the EC50, EC90 and EC99
of the individual samples the correlation coefficient between two substances is calcu-
lated. The interaction analysis, where the sensitivity of the individual substances are
compared with the sensitivity of combinations is done with the Variance analysis (Sokal
and F. James Rohlf, 1995) with the following formula:
t= x1−x2√
(V 1+V 2) · 1/n
The term t is the probability that the difference is merely due to chance. x1 and x2
denote the difference of the incidences, n is the number of cases incorporated in the
analysis and V1 as well as V2 the variances between the two sets of figures.
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The following tables and figures of the results are listed in a certain order
beginning with the % inhibition of schizont maturation (SMI%). This relative SMI%
shows the maturation inhibition of schizonts with increasing drug concentration com-
pared with the control well A and gives information about the relative activity of the
tested substances.
The next table shows the regression parameters. Important in this table are the
correlation of regression (r) and the function out of it the heterogeneity (χ2), as well
as the slope function (S). According to Litchfield and Wilcoxon (1949) a steep slope
function (S <2) shows a full activity in a narrow concentration-range, whereas a flat
slope function ( S >8) could be a sign for decreasing sensitivity.
In the following tables are the calculated mean effective drug concentrations (EC) and
the 95% confidence interval.
After that the regression analysis as well as the effective doses are presented graphi-
cally.
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5.1 Activity of tested drugs
A cut-off concentration could not be calculated for any of the tested substances.
5.1.1 Activity of Artemisinin
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more than
10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
53,58%
The relative schizont maturation inhibition (SMI%) for Artemisinin at the concentra-
tion 3nmol/l is 20,31% increases constantly up to the concentration 3000nmol/l with
92,32% (shown in Tab. 5.1), but never reaches 100% the total maturation inhibition.
Table 5.1: Drug concentration (Artemisinin) and SMI%
Drug conc. SMI%
3,0 20,31
10,0 35,22
30,0 55,35
100,0 68,63
300,0 80,26
1000,0 87,63
3000,0 92,32
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Table 5.2: Regression parameters of Artemisinin*
n = 29 S = 19,4581 fs = 2,7147
a = 3,8853 A = 4,0674 fEC-50 = 1,9794
b = 0,3350 K = 7 fEC-90 = 4,3358
r = 0,9942 N’ = 145 fEC-95 = 5,9518
χ2 = 0,6576 R = 1000 fEC-99 = 11,5216
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.3: EC values: Artemisinin
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0269 0,0023 0,3098
EC16 1,4317 0,7233 2,8340
EC50 27,8586 14,0741 55,1441
EC84 542,0753 273,8548 1072,9980
EC90 1277,0471 294,5380 5536,9748
EC95 3776,8250 634,5657 22479,0063
EC99 28865,3737 2505,3266 332575,3264
The regression analysis of the inhibition of schizont maturation through Artemisinin
is also represented graphically in Fig. 5.1, as well as the effective dose in Fig. 5.2.
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Figure 5.1: Regression analysis of Artemisinin
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Figure 5.2: Effective doses of Artemisinin
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5.1.2 Activity of Eury 1
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more than
10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
40,27%
The relative schizont maturation inhibition (SMI%) for Eury 1 at the concentration
3nmol/l is 14,71% and increases constantly up to the concentration 3000nmol/l with
81,05% (shown in Ta. 5.4), but never reaches 100% the total maturation inhibition.
Table 5.4: Drug concentration (Eury 1) and SMI%
Drug conc. SMI%
3,0 14,71
10,0 28,53
30,0 38,97
100,0 45,00
300,0 60,75
1000,0 71,55
3000,0 81,05
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Table 5.5: Regression parameters of Eury 1*
n = 29 S = 41,6637 fs = 3,7908
a = 3,7384 A = 9,1621 fEC-50 = 2,0649
b = 0,2666 K = 7 fEC-90 = 6,5403
r = 0,9948 N’ = 203 fEC-95 = 10,1272
χ2 = 0,4504 R = 1000 fEC-99 = 24,8886
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.6: EC values: Eury 1
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0184 0,0007 0,4592
EC16 2,7233 1,3188 5,6234
EC50 113,4614 54,9467 234,2906
EC84 4727,2259 2289,2838 9761,4216
EC90 13874,2892 2121,3590 90741,7865
EC95 54190,5172 5350,9626 548800,7233
EC99 697799,1449 28036,9133 17367234,4752
The regression analysis of the inhibition of schizont maturation through Eury 1 is also
represented graphically in Fig. 5.3, as well as the effective dose in Fig. 5.4.
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Figure 5.3: Regression analysis of E. longifolia 1 extract
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Figure 5.4: Effective doses of E. longifolia 1 extract
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5.1.3 Activity of Eury 2
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more than
10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
43,10%
The relative schizont maturation inhibition (SMI%) for Eury 2 at the concentration
3nmol/l is 14,47% and increases constantly up to the concentration 3000nmol/l with
82,02% (shown in Tab. 5.7), but never reaches 100% the total maturation inhibition.
Table 5.7: Drug concentration (Eury 2) and SMI%
Drug conc. SMI%
3,0 14,47
10,0 24,43
30,0 38,20
100,0 50,33
300,0 66,68
1000,0 75,63
3000,0 82,02
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Table 5.8: Regression parameters of Eury 2*
n = 29 S = 30,0079 fs = 3,7116
a = 3,6628 A = 6,3117 fEC-50 = 2,1868
b = 0,2924 K = 7 fEC-90 = 6,5266
r = 0,9964 N’ = 145 fEC-95 = 9,9845
χ2 = 0,3539 R = 1000 fEC-99 = 24,0399
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.9: EC values: Eury 2
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0340 0,0014 0,8162
EC16 3,2294 1,4767 7,0621
EC50 96,9067 44,3135 211,9197
EC84 2907,9698 1329,7575 6359,2711
EC90 7763,3631 1189,5007 50668,1559
EC95 26896,6276 2693,8322 268549,9745
EC99 276600,7487 11505,9012 6649455,1797
The regression analysis of the inhibition of schizont maturation through Eury 2 is also
represented graphically in Fig. 5.5, as well as the effective dose in Fig. 5.6.
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Figure 5.5: Regression analysis of E. longifolia 2 extract
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Figure 5.6: Effective doses of E. longifolia 2 extract
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5.1.4 Activity of Eury 3
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more than
10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
40,48%.
The relative schizont maturation inhibition (SMI%) for Eury 3 at the concentration
3nmol/l is 12,38% and increases constantly up to the concentration 3000nmol/l with
85,31% (shown in Tab. 5.10), but never reaches 100% the total maturation inhibition.
Table 5.10: Drug concentration (Eury 3) and SMI%
Drug conc. SMI%
3,0 12,38
10,0 23,92
30,0 34,17
100,0 44,86
300,0 67,12
1000,0 78,23
3000,0 85,31
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Table 5.11: Regression parameters of Eury 3*
n = 29 S = 21,4589 fs = 2,9027
a = 3,4988 A = 4,4685 fEC-50 = 2,0245
b = 0,3243 K = 7 fEC-90 = 4,7329
r = 0,9958 N’ = 145 fEC-95 = 6,6492
χ2 = 0,5121 R = 1000 fEC-99 = 13,4864
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.12: EC values: Eury 3
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0786 0,0058 1,0597
EC16 4,7701 2,3562 9,6570
EC50 102,3605 50,5609 207,2288
EC84 2196,5473 1084,9825 4446,9105
EC90 5323,0386 1124,6793 25193,6182
EC95 16315,8003 2453,8079 108486,6247
EC99 133347,3393 9887,5680 1798370,7250
The regression analysis of the inhibition of schizont maturation through Eury 3 is also
represented graphically in Fig. 5.7, as well as the effective dose in Fig. 5.8.
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Figure 5.7: Regression analysis of E. longifolia 3 extract
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Figure 5.8: Effective doses of E. longifolia 3 extract
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5.1.5 Activity of Eury 1 plus Artemisinin
Artemisinin was combined with Eury 1 (1:1) in order to test the interaction of these
drugs in vitro.
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more
than 10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
35,38%.
The relative schizont maturation inhibition (SMI%) for Eury 1 plus Artemisinin at
the concentration 3nmol/l is 18,96% and increases constantly up to the concentration
3000nmol/l with 92,35% (shown in Tab. 5.13), but never reaches 100% the total matu-
ration inhibition.
Table 5.13: Drug concentration (Eury 1 plus Artemisinin) and SMI%
Drug conc. SMI%
3,0 18,96
10,0 30,97
30,0 44,08
100,0 52,66
300,0 70,93
1000,0 84,30
3000,0 92,34
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Table 5.14: Regression parameters of Eury 1 plus Artemisinin*
n = 29 S = 21,3587 fs = 2,6375
a = 3,7245 A = 4,4482 fEC-50 = 1,9020
b = 0,3248 K = 7 fEC-90 = 4,1174
r = 0,9948 N’ = 174 fEC-95 = 5,6098
χ2 = 0,6092 R = 1000 fEC-99 = 10,6762
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.15: EC values: Eury 1 plus Artemisinin
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0394 0,0037 0,4203
EC16 2,3749 1,2486 4,5169
EC50 50,7239 26,6693 96,4749
EC84 1083,3973 569,6211 2060,5798
EC90 2621,9225 636,7947 10795,4374
EC95 8022,7988 1430,1383 45006,3466
EC99 65359,5184 6121,9852 697791,0812
The regression analysis of the inhibition of schizont maturation through Eury 1 plus
Artemisinin is also represented graphically in Fig. 5.9, as well as the effective dose in
Fig. 5.10.
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Figure 5.9: Regression analysis of Artemisinin plus E. longifolia 1 extract
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5.1 Activity of tested drugs
Figure 5.10: Effective doses of Artemisinin plus E. longifolia 1 extract
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5.1.6 Activity of Eury 2 plus Artemisinin
Artemisinin was combined with Eury 2 (1:1) in order to test the interaction of these
drugs in vitro.
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more
than 10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
34,66%.
The relative schizont maturation inhibition (SMI%) for Eury 1 plus Artemisinin at
the concentration 3nmol/l is 18,28% and increases constantly up to the concentration
3000nmol/l with 90,90% (shown in Tab. 5.16), but never reaches 100% the total matu-
ration inhibition.
Table 5.16: Drug concentration (Eury 2 plus Artemisinin) and SMI%
Drug conc. SMI%
3,0 18,28
10,0 33,58
30,0 48,80
100,0 65,48
300,0 79,03
1000,0 85,48
3000,0 90,90
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Table 5.17: Regression parameters of Eury 2 plus Artemisinin*
n = 29 S = 19,9536 fs = 2,7612
a = 3,8091 A = 4,1657 fEC-50 = 1,9909
b = 0,3322 K = 7 fEC-90 = 4,4333
r = 0,9951 N’ = 145 fEC-95 = 6,1216
χ2 = 0,5378 R = 1000 fEC-99 = 11,9915
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.18: EC values: Eury 2 plus Artemisinin
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0328 0,0027 0,3932
EC16 1,8059 0,9071 3,5954
EC50 36,0345 18,0995 71,7415
EC84 719,0197 361,1511 1431,5041
EC90 1706,2443 384,8663 7564,3674
EC95 5092,7366 831,9261 31175,8037
EC99 39599,0921 3302,2740 474850,9971
The regression analysis of the inhibition of schizont maturation through Eury 2 plus
Artemisinin is also represented graphically in Fig. 5.11, as well as the effective dose in
Fig. 5.12.
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Figure 5.11: Regression analysis of Artemisinin plus E. longifolia 2 extract
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5.1 Activity of tested drugs
Figure 5.12: Effective doses of Artemisinin plus E. longifolia 2 extract
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5.1.7 Activity of Eury 3 plus Artemisinin
Artemisinin was combined with Eury 3 (1:1) in order to test the interaction of these
drugs in vitro.
Out of the 36 isolates, 29 (80,5%) have an adequate maturation of schizonts (more
than 10% schizonts in well A).
The arithmetic mean schizont concentration in well A per 200 asexual parasites was
37,79%.
The relative schizont maturation inhibition (SMI%) for Eury 1 plus Artemisinin at
the concentration 3nmol/l is 18,69% and increases constantly up to the concentration
3000nmol/l with 93,03% (shown in Tab. 5.19), but never reaches 100% the total matu-
ration inhibition.
Table 5.19: Drug concentration (Eury 3 plus Artemisinin) and SMI%
Drug conc. SMI%
3,0 18,69
10,0 34,08
30,0 48,78
100,0 60,37
300,0 79,68
1000,0 87,84
3000,0 93,03
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Table 5.20: Regression parameters of Eury 3 plus Artemisinin*
n = 29 S = 17,4134 fs = 2,5228
a = 3,7563 A = 3,6694 fEC-50 = 1,9295
b = 0,3481 K = 7 fEC-90 = 3,9386
r = 0,9968 N’ = 145 fEC-95 = 5,2716
χ2 = 0,3670 R = 1000 fEC-99 = 9,6968
*According to Litchfield and Wilcoxon (1949): n=number of isolates, a=intercept of regression, b=slope of regression, r=correlation of
regression, χ2=heterogeneity, S=slope function, A=intermediate term for fs, K=number of drug concentration, N’= number of data points
EC16 to EC84, R=highest/lowest drug concentration tested, fs=factor of S, fEC=multiplication/division factor for obtaining 95%
confidence intervals of EC
Table 5.21: EC values: Eury 3 plus Artemisinin
EC Mean 95% Confidence Intervals
Lower Higher
EC1 0,0446 0,0046 0,4323
EC16 2,0460 1,0604 3,9477
EC50 35,6274 18,4645 68,7437
EC84 620,3960 321,5296 1197,0632
EC90 1415,4586 359,3776 5574,9797
EC95 4019,7928 762,5400 21190,6697
EC99 28472,0333 2936,2345 276087,1714
The regression analysis of the inhibition of schizont maturation through Eury 3 plus
Artemisinin is also represented graphically in Fig. 5.13, as well as the effective dose in
Fig. 5.14.
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Figure 5.13: Regression analysis of Artemisinin plus E. longifolia 3 extract
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5.1 Activity of tested drugs
Figure 5.14: Effective doses of Artemisinin plus E. longifolia 3 extract
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6 Discussion and Conclusion
6.1 Activity and Regression Analysis
6.1.1 Artemisinin
The evaluation of the activity of Artemisinin shows for the test isolates an EC50 of
27,8586 nmol/l, an EC90 of 1277,0471 nmol/l and an EC99 of 28865,3737 nmol/l. Com-
pared with data from 2009 (Kerschbaumer et al., 2010), shown in table 6.1, there is a
big increase in these values. This leads to the assumption that there is a decrease in
effectiveness of Artemisinin in this area.
Table 6.1: Comparison of EC values 2009, 2010
Art 2009 2010
EC50 8,1181 27,8586
EC90 137,2319 1277,0471
EC99 1375,6520 28865,3737
The regression lines of Artemisinin from 2009 and 2010, shown in table 6.2 are com-
pared for parallelism and activity differences. The slope ratio of the regression lines,
shown in table 6.3 can be considered as parallel, since fSR >SR. Therefore the two could
be compared for an efficacy difference, shown as well in table 6.3.
Table 6.2: Regression parameters of Artemisinin 2009/2010
Art S fs
2009 8,9733 1,7836
2010 19,4581 2,7147
S = slope function, fs = factor of S
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Table 6.3: Comparison of regression parameters Artemisinin 2009/2010
Art
2009/
2010
SR fSR Slope of
regres-
sion
PR fPR
2,1684 3,1714 parallel
EC50 3,4321 2,3810 significant
EC90 9,3057 5,6588 significant
EC99 20,9830 17,2484 significant
SR = slope ration, fSR = factor of SR, PR = potency ratio, fPR = factor of PR
The comparison of regression parameters confirm the assumption above that there is
a loss of Artemisinin sensitivity between 2009 and 2010. In all three EC values (50, 90,
99) the potency ratio (PR) >factor of PR (fPR) at the 95% confidence level.
6.2 Variance analysis of resulting data
6.2.1 Analysis for Interaction between Artemisinin and
Eurycoma 1, 2, 3 in P. falciparum
Variance analysis was applied since the mixture of Artemisinin and the parallel adminis-
tered Eurycomanons 1 and 2 charges resulted in P. falciparum always in a significantly
lower antiplasmodial activity as compared to freshly prepared 0,5 Artemisinin and Eury
1 and 2 charges. This indicates that the Artemisinin+Eury charge prepared at the In-
stitute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna has
lost part of its activity due to long contact between Artemisinin and the Eurycomanone
charge. With regard to Eurycomanon 3 it was probably an incompatibility between
Artemisinin and the Eurycomanon. At the same time, the comparison between the two
formulations indicated in freshly prepared Artemisinin-Eury-1 and Artemisinin-Eury-2
synergism at the EC50 and EC90 in P. falciparum.
Eury-1 - Art at EC50
Result: 6,0993 −→ significant synergism
Degree of Freedom 54 (=2,6908 at p=0,01)
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6.2 Variance analysis of resulting data
Eury-2 - Art at EC50
Result: 19,0742 −→ significant synergism
Degree of Freedom 56 (= 2,6952 at p=0,01)
Eury-3 - Art at EC50
Result: Inhibition under Eury-3 - Art higher than under separate compounds
Eury-1 - Art at EC90
Result: 11,3260 −→ significant synergism
Degree of Freedom 58 (=2,6864 at p=0,01)
Eury-2 - Art at EC90
Result: 9,2170 −→ significant synergism
Degree of Freedom 58 (=2,6952 at p=0,01)
Eury-3 - Art at EC90
Result: Inhibition under Eury-3 - Art higher than under separate compounds
In P. falciparum the isolates showed in Eury-1-Art and Eury-2-Art a significant syn-
ergism, albeit at indices strongly reduced from the experience in P. vivax. This was
obviously due to the reduced activity of Artemisinin.
Follow up on these observations it would be reasonable to investigate potential advan-
tages of Eurycomanones together with Artemisinin in areas with Artemisinin-sensitive
P. falciparum strains.
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Table 7.4: Summary sheet Mae Sot 2010 P. falciparum
Isolate no. As Par / ţl % M+ troph Well A Schiz/200 Result Comments
1 14518 12 5 20 Valid WHW
2 34225 20% 35 Valid Good
3 8889 30% 32 Valid WHW
4 9250 28% 61 Valid Good
5 83429 59% 20 Valid WHW
6 99999 35% 70 Valid Good
7 69333 23% 75 Valid Good
8 15059 10% washed out Invalid OUT
9 29818 17% 20 Valid WHW
10 44444 32% 97 Valid Good
11 21053 15% 36 Valid Good
12 17200 27% 20 Valid WHW
13 1300 62% 23 Valid WHW
14 19750 17% 3 Invalid OUT
15 26233 20% 20 Valid WHW
16 74812 15% 20 Valid WHW
17 38400 35% 20 Valid WHW
18 2576 40% 96 Valid Good
19 9697 20% 53 Valid Good
20 18963 25% <4 Invalid OUT
21 2791 10% 20 Valid WHW
22 87999 10% 28 Valid WHW
23 26371 20% 44 Valid Good
24 42250 25% 51 Valid Good
25 6154 25% 47 Valid Good
26 49846 30% 23 Valid Good
27 61429 20% 40 Valid Good
28 6323 25% 62 Valid WHW
29 2196 30% 56 Valid WHW
30 30737 15% <20 Invalid OUT
31 17561 25% 20 Valid WHW
32 22400 20% 57 Valid WHW
33 9085 20% 59 Valid WHW
34 2222 20% 63 Valid WHW
35 32400 25% <20 Invalid OUT
36 2727 25% 55 Valid GOOD
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Table 7.5: Schizont count Pf 2010 Artemisinin
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 70,37 51,85 33,33 25,93 14,81 7,41 3,7
2 100 82,5 25 17,5 5 2,5 0 0
3 100 100 86,21 74,14 36,31 17,24 Jan 00 5,17
4 100 81,25 75 39,58 43,75 25 25 2,08
5 100 89,29 80,36 16,07 3,57 1,79 0 0
6 100 93,65 93,65 93,65 57,14 34,92 26,98 15,87
7 100 81,25 81,25 18,75 10,42 4,17 2,08 0
9 100 70 27,5 17,5 10 7,5 5 2,5
10 100 85,11 65,96 29,79 34,04 23,4 19,15 19,15
11 100 75,25 68,75 62,5 37,6 18,75 12,5 3,13
12 100 76,75 58,14 48,84 39,54 23,26 13,95 4,65
13 100 83,96 70,76 49,06 33,96 26,42 20,75 15,09
15 100 59,09 36,36 27,27 22,73 13,64 9,09 0
16 100 67,74 45,16 25,81 9,68 3,23 0 0
17 100 71,88 51,56 32,81 21,88 18,75 15,63 12,5
18 100 94,83 67,24 37,93 24,14 15,52 10,34 3,45
19 100 60 50 40 23,33 23,33 10 0
21 100 90 80 53,33 30 23,33 20 13,33
22 100 100 100 72,33 52,78 22,22 8,33 2,78
23 100 65,79 68,42 52,63 50 52,63 28,95 28,95
24 100 62,07 48,28 31,03 20,69 17,24 17,24 23,79
25 100 79,41 58,82 58,82 50 44,12 23,53 23,53
27 100 78,57 60,71 35,71 10,71 3,57 0 0
28 100 80 66,67 46,67 33,33 16,67 6,67 0
29 100 76,36 58,18 38,18 25,54 9,09 3,64 0
31 100 76,32 57,89 39,47 26,32 18,42 13,16 7,89
32 100 94,44 88,89 59,26 38,89 11,11 3,7 1,85
33 100 94,74 89,47 76,32 65,79 13,16 2,63 0
36 100 70,37 66,67 66,67 66,67 66,67 44,44 33,33
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Table 7.6: Schizont count Pf 2010 Eury-1
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 85,72 71,43 61,9 52,38 42,86 33,33 9,52
2 100 93,33 62,22 60 42,22 40 13,33 6,67
3 100 102,78 102,78 66,57 41,67 25 13,89 5,56
4 100 103,45 84,49 77,59 70,69 65,52 55,17 55,17
5 100 80 64,44 60 53,33 15,56 4,44 2,22
6 100 81,4 84,88 81,4 79,07 75,59 72,09 16,28
7 100 68,25 53,96 38,09 34,92 23,81 22,22 3,17
9 100 81,82 63,64 63,64 63,64 18,18 4,55 0
10 100 80,3 80,3 63,64 68,18 50 36,36 9,09
11 100 91,31 82,61 69,57 60,87 52,17 47,83 39,13
12 100 91,43 62,86 48,57 31,43 25,71 20 14,29
13 100 89,71 80,88 63,24 48,53 44,12 41,18 38,24
15 100 62,86 40 25,71 17,14 11,43 8,57 5,71
16 100 95 90 85 85 55 35 15
17 100 97,87 96,76 72,34 66,32 44,68 36,17 31,92
18 100 121,05 103,05 108,77 105,26 52,63 19,3 7,02
19 100 64,29 42,86 28,57 28,57 14,29 10,71 7,14
21 100 81,54 67,69 55,39 46,16 30,77 21,54 13,85
22 100 83,05 67,8 57,63 50,85 20,34 8,47 3,39
23 100 65 45 40 40 40 40 35
24 100 92,59 86,19 77,78 70,37 66,67 44,44 44,44
25 100 85 70 55 95 45 40 35
27 100 100 100 100 80 64 12 0
28 100 86,21 75,86 62,07 48,28 31,03 17,24 6,9
29 100 71,43 51,43 48,57 45,72 42,86 42,86 37,14
31 100 58,62 34,48 27,59 17,24 10,34 6,9 3,45
32 100 81,58 65,79 57,9 52,83 36,84 26,32 15,79
33 100 77,78 61,11 33,33 19,44 13,89 11,11 8,33
36 100 100 80 80 80 80 80 80
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Table 7.7: Schizont count Pf 2010 Eury-2
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 70 50 35 25 15 10 0
2 100 82,86 85,72 58,57 48,57 32,86 32,86 20
3 100 100 100 64,29 42,86 43,86 42,86 28,57
4 100 100 97,78 97,78 95,55 66,67 46,67 31,11
5 100 77,09 60,42 50 41,67 16,67 6,25 2,08
6 100 100 89,59 70,84 52,09 38,54 20,83 7,29
7 100 73,17 56,1 56,1 56,1 9,76 4,88 4,88
9 100 85,71 71,43 66,66 57,14 47,62 42,86 38,1
10 100 96,72 93,45 92,81 42,62 8,2 3,29 1,64
11 100 65 40 35 30 20 15 10
12 100 69,23 46,15 46,15 42,31 42,31 42,31 38,46
13 100 90,91 81,82 63,64 48,49 39,39 33,33 27,27
15 100 84 68 60 52 32 20 8
16 100 90 85 70 55 30 15 5
17 100 97,56 92,68 68,29 48,78 34,15 21,95 12,2
18 100 84,62 69,23 53,65 42,31 34,62 19,23 11,54
19 100 70 45 40 25 0 0 0
21 100 94,74 89,47 84,21 81,6 36,84 15,79 7,89
22 100 100 100 77,5 60 27,5 12,5 5
23 100 100 100 95 95 90 85 85
24 100 92 88 76 68 64 64 64
25 100 75 60 50 45 40 30 25
27 100 100 100 55,56 22,22 14,81 0 0
28 100 90,91 81,82 63,64 51,52 39,39 27,27 15,15
29 100 66,67 45,1 41,18 39,22 33,33 29,41 25,49
31 100 70 50 30 20 10 6,67 3,33
32 100 97,5 92,5 70 52,5 35 22,5 12,5
33 100 97,73 93,18 61,36 40,91 18,18 9,09 4,55
36 100 59,09 59,09 59,09 59,09 45,46 27,27 27,27
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Table 7.8: Schizont count Pf 2010 Eury-3
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 65,22 43,48 39,13 39,13 17,39 8,7 4,35
2 100 92,13 82,02 74,16 34,83 14,61 8,99 2,25
3 100 66,67 42,86 38,1 33,33 28,57 23,81 19,05
4 100 100 100 100 93,94 34,85 22,73 16,67
5 100 96,3 88,89 85,19 81,48 25,93 7,41 3,7
6 100 100 100 84,16 84,16 50,5 30,69 7,92
7 100 100 95 90 85 20 20 0
9 100 75 55 50 45 30 20 10
10 100 96,55 72,41 60,34 50 3,45 0 0
11 100 66,67 43,33 30 20 13,33 10 6,67
12 100 88,89 80,56 66,67 58,33 52,78 47,22 41,67
13 100 88,71 77,42 59,68 46,77 35,48 24,19 17,74
15 100 94,74 89,47 84,21 78,95 44,74 26,32 10,53
16 100 89,29 78,57 46,43 28,57 17,86 10,71 3,57
17 100 78,57 61,43 41,43 28,57 18,57 11,43 4,29
18 100 100 100 102,94 102,94 102,94 32,35 32,35
19 100 85,71 71,43 61,9 42,86 19,05 14,29 9,52
21 100 64,44 41,11 32,22 25,56 16,67 10 6,67
22 100 83,67 71,43 53,06 38,78 20,41 10. Jan 4,08
23 100 100 100 100 85 80 80 80
24 100 100 100 100 100 68,18 59,09 54,55
25 100 85 70 45 40 40 40 25
27 100 78,06 73,17 70,73 19,51 12,2 4,88 0
28 100 92,5 85 67,5 55 25 12,5 5
29 100 80 65 62,5 60 45 35 25
30 100 92 80 52 32 16 8 4
32 100 85,37 73,17 65,85 58,54 34,15 19,51 7,32
33 100 95,45 95,45 90,91 90,91 40,91 18,18 9,09
36 100 100 70 55 40 25 15 15
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Table 7.9: Schizont count Pf 2010 Eury-1-Art
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 51,61 35,48 22,58 16,13 12,9 6,45 0
2 100 97,62 73,81 23,81 19,05 14,29 14,29 0
3 100 57,69 34,62 34,62 34,62 15,38 7,69 0
4 100 111,9 88,1 73,81 73,81 38,1 23,61 4,76
5 100 33,33 11,11 5,56 0 0 0 0
6 100 90,59 82,35 78,82 75,29 72,94 24,71 7,06
7 100 87,18 74,36 74,36 74,36 25,64 7,69 5,13
9 100 50 25 25 25 10 5 0
10 100 98,48 96,97 95,45 93,94 90,91 13,64 3,03
11 100 89,66 79,31 51,72 51,72 27,59 20,69 13,79
12 100 75,86 55,17 41,38 31,03 13,79 6,9 3,45
13 100 97,37 94,74 92,11 89,47 44,74 23,68 5,26
15 100 88,46 76,92 73,08 69,23 26,92 11,54 0
16 100 85,71 71,43 38,1 14,29 4,76 0 0
17 100 81,4 65,12 46,51 30,23 18,6 9,3 2,33
18 100 83,72 93,02 79,07 60,47 34,88 4,65 0
19 100 85,71 76,19 71,43 71,43 66,67 61,9 23,81
21 100 100 100 68,57 45,71 20 8,57 2,86
22 100 58,18 34,55 25,45 16,36 5,45 1,82 0
23 100 90,48 80,95 66,67 57,14 35,71 35,71 35,71
24 100 88 88 88 76 72 72 72
25 100 80 64 64 52 48 36 24
27 100 70,97 67,74 64,52 58,06 32,26 9,68 3,23
28 100 67,65 47,06 44,12 41,18 14,71 5,88 0
29 100 86,67 76,67 56,67 40 16,67 6,67 0
31 100 96,3 88,89 66,67 44,44 18,52 7,41 0
32 100 90,63 68,75 56,25 46,88 18,75 6,25 3,13
33 100 96,55 93,1 51,72 27,59 13,79 6,9 0
36 100 58,33 58,33 41,67 37,5 29,17 16,67 12,5
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Table 7.10: Schizont count Pf 2010 Eury-2-Art
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 68 44 36 32 16 8 4
2 100 93,1 89,66 48,28 41,38 37,93 27,59 3,45
3 100 80,95 66,67 38,1 23,81 14,29 9,52 4,78
4 100 92,86 88,1 69,05 50 38,1 14,29 2,38
5 100 72,41 37,93 10,34 0 0 0 0
6 100 81,05 74,74 68,42 42,11 30,53 24,21 2,11
7 100 71,43 66,67 45,24 7,14 4,76 4,76 2,11
9 100 77,27 59,09 31,82 18,18 13,64 9,09 4,55
10 100 115,38 98,46 64,62 24,62 24,62 24,62 24,62
11 100 100 100 100 50 30 20 20
12 100 96,55 62,07 41,38 27,59 24,14 20,69 17,24
13 100 66,67 26,19 19,05 11,9 4,76 0 0
15 100 84,62 69,23 42,31 26,92 19,23 11,54 0
16 100 68 48 36 24 8 0 0
17 100 75,61 56,1 43,9 34,15 19,51 9,76 4,88
18 100 94,29 71,43 68,57 65,71 14,29 11,43 0
19 100 75 60,71 50 39,29 28,57 17,86 17,86
21 100 97,22 91,67 86,11 83,33 25 8,33 2,78
22 100 70 50 34 22 14 10 4
23 100 74,07 55,56 51,85 51,85 51,85 51,85 51,85
24 100 88,24 73,53 61,76 55,88 44,12 44,12 44,12
25 100 62,5 64,17 41,67 37,5 33,33 33,33 25
27 100 80,65 80,65 67,74 19,35 9,68 0 0
28 100 78,79 60,61 48,48 39,39 15,15 6,06 0
29 100 78,95 63,18 52,63 42,11 15,79 5,26 0
31 100 71,43 50 32,14 21,43 14,29 7,14 0
32 100 57,58 33,33 30,3 27,27 12,12 6,06 3,03
33 100 97,14 94,29 90 37,14 14,29 5,71 0
36 100 100 90 75 45 30 30 25
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Table 7.11: Schizont count Pf 2010 Eury-3-Art
A B C D E F G H
Pat
No
Control
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
Conc.
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 86,96 78,26 69,57 60,87 21,74 8,7 0
2 100 87,23 65,96 40,43 12,77 10,64 6,38 0
3 100 34,09 11,36 9,09 4,55 4,55 4,55 2,27
4 100 94,12 94,12 85,29 41,18 29,41 8,82 0
5 100 53,33 30 16,67 10 6,67 0 0
6 100 100 84,04 63,83 50 22,34 20,21 9,57
7 100 79,31 62,07 50 15,52 5,17 3,45 3,45
9 100 91,3 86,96 39,13 17,39 8,7 0 0
10 100 73,42 54,43 40,51 30,38 12,66 7,59 7,59
11 100 78,13 59,38 46,88 25 18,75 15,63 6,25
12 100 104,17 108,33 95,83 83,33 25 8,33 4,17
13 100 55,81 30,23 16,28 93,02 6,98 6,98 4,65
15 100 75 58,33 36,11 22,22 13,89 8,33 0
16 100 83,33 66,67 33,33 16,67 12,5 8,33 4,17
17 100 82,76 65,52 48,28 34,48 13,79 3,45 0
18 100 92,5 85 80 50 22,5 7,5 0
19 100 81,82 63,64 54,55 50 22,73 13,64 0
21 100 97,33 92 60 38,67 17,33 8 4
22 100 75,56 55,56 48,89 42,22 20 8,89 4,44
23 100 96 92 84 80 76 68 60
24 100 95,65 69,57 65,22 60,87 52,17 47,83 43,48
25 100 76 56 48 44 28 16 8
27 100 93,33 86,67 76,67 56,67 40 16,67 16,67
28 100 67,35 44,9 26,53 16,33 8,16 4,08 0
29 100 80 63,33 53,33 43,33 16,67 6,67 0
31 100 79,31 65,52 58,62 48,28 17,24 6,9 0
32 100 65,52 44,83 37,93 31,03 13,79 6,9 3,45
33 100 82,76 68,97 48,28 34,48 13,79 6,9 0
36 100 96 68 52 36 28 24 20
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